|
Botulinum Toxin for the Treatment of Involuntary Movement Disorders Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Botulinum Toxin for the Treatment of Involuntary Movement Disorders conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Botulinum Toxin for the Treatment of Involuntary Movement Disorders Clinical research trials and Botulinum Toxin for the Treatment of Involuntary Movement Disorders health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Botulinum Toxin for the Treatment of Involuntary Movement Disorders. Botulinum Toxin for the Treatment of Involuntary Movement Disorders Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Botulinum Toxin for the Treatment of Involuntary Movement Disorders clinical trial. Human subjects often get the best healthcare available for their Botulinum Toxin for the Treatment of Involuntary Movement Disorders condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Botulinum Toxin for the Treatment of Involuntary Movement Disorders  Botulinum Toxin for the Treatment of Involuntary Movement Disorders
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
For Condition: Chorea,Drug Induced Dyskinesia,Movement Disorder,Muscular Disease,Tic Disorder
Status: Recruiting
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: Botulism is a severe form of food poisoning caused by bacteria. This bacteria produces several toxins one of which is botulinum toxin A. This toxin causes the symptoms of food poisoning. Small amounts of botulinum toxin A have been used to treat speech disorders such as stuttering and problems with the muscles of the eyes. The study examines the effectiveness of botulinum toxin as treatment for a variety of movement disorders. The goals of the study are to refine the technique of treatment to provide the best results, to improve the understanding of how botulinum toxin works on movement disorders, and find other conditions that may be treatable with botulinum toxin. In addition, researchers also plan to study the possible use of botulinum toxin F alone and in combination with botulinum toxin A in patients who do not respond to botulinum A toxin treatment.
Details: The efficacy of botulinum toxin (btx) has now been demonstrated for a variety of diseases associated with involuntary muscle spasms or movement. The application of botulinum toxin therapy to movement disorders requires treatment tailored to the individual patient and specific techniques of injection. This protocol 1) provides for training of physicians in the use of botulinum toxin and 2) allows us to provide botulinum toxin injections for patients participating in other studies on physiology of dystonia, and other muscle spasms and physiological effects of botulinum toxin.
Eligibility:
Study Type: Interventional, Training
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Patients will be eligible for participation if they have a movement disorder that, in the judgment of the treating physician, might be amenable to treatment with botulinum toxin. Applicable disorders include but are not limited to dystonia, hemifacial spasm, blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, spasmodic dysphonia with or without prior recurrent laryngeal nerve resection or thyroplasty. EXCLUSION CRITERIA: Patients will be excluded form participation if 1. They are pregnant or breastfeeding. 2. They have a known motor neuron or neuromuscular junction disease (amyothropic lateral sclerosis, myasthenia gavis, Eaton-Lamert Syndrome). 3. They require treatment with an aminoglycoside antibiotic. 4. They have a paradoxical vocal fold movement with intermittent stridor due to either gastroesophageal reflux or emotional disorders.
Total Enrollment: 800
Location and Contact Information:
National Institute of Neurological Disorders and Stroke (NINDS) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 850195; 85-N-0195
Study Start Date: November 21, 1985
Record last reviewed: November 20, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001208
Other Muscular Disease Studies:
1. Botulinum Toxin for the Treatment of Involuntary Movement Disorders
2. Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated with Streptococcal Infections
3. Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)
Related Studies:
Other Muscular Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
|
|
|
|
|
|
|
|
